Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of MWN105 in non-diabetic overweight or obese adults
CTR20253336Phase 2Active
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Sep 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MWN105 in obesity and Overweight (4 arms), sponsored by Shanghai Minwei Biotechnology Co., Ltd. Primary endpoint: Percent change in body weight from baseline. Started Sep 2025; status: active.
02
Drugs
MWN105
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20253336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253336.